Navigation Links
Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
Date:6/3/2011

ate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Media Contact: Meghan Weber
Sullivan & Associates
(917) 399-8713
news@cornerstonepharma.com


'/>"/>
SOURCE Cornerstone Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... SOUTH PLAINFIELD, N.J. , May 16, 2013 /PRNewswire/ ... a registration statement on Form S-1 with the U.S. ... initial public offering of its common stock. The number ... for the offering have not been determined. ... and Credit Suisse are acting as joint book-running managers ...
(Date:5/16/2013)... N.C. , May 16, 2013  Today, the ... North Carolina House of Representatives recently approved ... for chemotherapy from charging patients higher out-of-pocket fees for ... formularies, many of which have more severe side-effects. However, ... limit of $300, which will continue to be a ...
(Date:5/16/2013)...  Alere Inc. (NYSE: ALR ), a global ... at home through the merger of rapid diagnostics and health ... on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B).  ... of record of Series B stock at the close of ... cover the amount of all dividends accrued from April 1, ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... June 20 Advocate Christ,Medical Center in Oak Lawn, ... the Chicago area, the only one in the Advocate ... are using a glue-like liquid for,the successful treatment of ... procedure, Thomas J. Grobelny MD, of,the medical center,s Neurosciences ...
... SYDNEY, Australia, June 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... the U.S. Food,and Drug Administration (FDA) have reached ... for bronchiectasis via the Special,Protocol Assessment process., ... a clinical trial protocol,intended to form the primary ...
Cached Medicine Technology:Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3
(Date:5/19/2013)... At a May 6th, 2013 meeting ... Physicians (NCAPIP), the Pacific Chronic Disease Coalition (PCDC), ... Disease Directors (NACDD), presented a newly published assessment ... non-communicable diseases (NCDs) in the U.S. Associated Pacific ... Hawaii Journal of Medicine and Public Health, highlights ...
(Date:5/19/2013)... 19 (HealthDay News) -- Although spring arrived late this ... allergy season will still be strong, according to a ... Dr. Richard Waguespack, clinical professor in the university,s ... in a robust summer allergy season. However, some simple ... wheezing and coughing, he added. "Tree pollen has ...
(Date:5/19/2013)... ─ Gourmands and foodies everywhere have long recognized ginger ... zing to both sweet and savory dishes; now, a ... of the spicy root also may have properties that ... of the study will be presented at the ATS ... a tightening of the bronchial tubes that carry air ...
(Date:5/19/2013)... MO (PRWEB) May 19, 2013 Healthcare ... May 19-22, 2013, at the Walt Disney World Swan ... trends in supply chain innovation, care delivery and healthcare ... different dynamic in all healthcare markets, with ... of the conversation,” said Todd Ebert, Amerinet president and ...
(Date:5/19/2013)... May 19, 2013 People in Minnesota have ... Altman Fitness is offering its 28 Day Fat Loss Formula. ... from the comfort of their own home. The product sells ... More information can be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , ... leave their houses now, but after using the 28 Day ...
Breaking Medicine News(10 mins):Health News:Pacific Island Public Health Group Declares Diabetes at Pandemic Proportions 2Health News:Pacific Island Public Health Group Declares Diabetes at Pandemic Proportions 3Health News:Managing Seasonal Allergies 2Health News:Ginger compounds may be effective in treating asthma symptoms 2Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2
... (HealthDay News) -- Child safety and booster seats protect children of ... finding of a new study that looked at nearly 1,000 children, ... of the children were properly restrained in the correct child safety ... report published online and in the December print issue of the ...
... want to be involved in decisions regarding quality of ... organs with a higher risk of failure, according to ... 42 percent of patients would choose to remain on ... liver according to the study,s lead author Michael L. ...
... 1, 2011 In a development that could pave ... clues to more common ones, physician-scientists at Albert ... Montefiore Medical Center , the University Hospital for ... site for the Network for Excellence in Neuroscience Clinical ...
... obstacle in the fight against cancer is that anticancer ... cells, resulting in significant side effects. Yet research into ... of specific cancer-causing mechanisms is hampered by lack of ... individual patients. "A major goal of cancer research ...
... DURHAM, N.C. -- Tracking individual cells within the lung ... University researchers new insights into the causes of Idiopathic ... treated now by lung transplantation. , IPF fills the ... tissue, progressively restricting breathing. The Duke University Medical Center ...
... of Hepatology , a journal of the American ... limitations in screening for primary liver cancer, also known ... if given the choice during a clinical trial, most ... non-screening, therefore making a randomized study of HCC screening ...
Cached Medicine News:Health News:Kids of All Weights Benefit From Car Seats 2Health News:Transplant candidates seek best quality livers, even if it means waiting longer 2Health News:Newly established neuroscience clinical trials center could bring treatments to patients faster 2Health News:Newly established neuroscience clinical trials center could bring treatments to patients faster 3Health News:Tumor-targeting compound points the way to new personalized cancer treatments 2Health News:Tumor-targeting compound points the way to new personalized cancer treatments 3Health News:Tumor-targeting compound points the way to new personalized cancer treatments 4Health News:New insights come from tracing cells that scar lungs 2Health News:Studies of patients with cirrhosis uncover limitations in liver cancer screening 2
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
Medicine Products: